GENEVA–(BUSINESS WIRE)–Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Author: Business Wire
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
GENEVA–(BUSINESS WIRE)–Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neu…
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
PARIS–(BUSINESS WIRE)–Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies…
GenSight Biologics annonce l’approbation de l’ensemble des résolutions soutenues par le Conseil d’Administration lors de son assemblée générale mixte du 13 mai 2025
PARIS–(BUSINESS WIRE)–Regulatory News: L’Assemblée Générale Mixte des actionnaires de la société GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today…
Die wichtigsten Ergebnisse der LIGHTSITE IIIB-Verlängerungsstudie von LumiThera zeigen eine anhaltende Verbesserung des Sehvermögens bei Patienten mit trockener AMD
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., ein Medizintechnikunternehmen, das Photobiomodulationsbehandlungen (PBM) für Augenschäden und -erkrankungen anbietet, hat heute die wichtigsten Ergebnisse der LIGHTSITE IIIB-Verlängerungsstudie bekannt gegeben,…
Riassunto: I risultati principali dello studio di estensione LIGHTSITE IIIB di LumiThera indicano un miglioramento prolungato della visione nei soggetti affetti da AMD secca
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., azienda produttrice di dispositivi medici che offre trattamenti di fotobiomodulazione (PBM) per i danni e le malattie oculari, ha annunciato oggi i risultati principali dello studio di estensione LIGHTSITE IIIB…
Samenvatting: Belangrijke analyseresultaten van het LIGHTSITE IIIB-verlengingsonderzoek van LumiThera tonen een uitgebreide verbetering van het zicht aan bij patiënten met droge LMD
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., een bedrijf gespecialiseerd in medische hulpmiddelen dat FBM-behandeling (fotobiomodulatie) voor oogschade en oogaandoeningen aanbiedt, maakte vandaag de belangrijkste analyseresultaten bekend van de LIGHTSITE …
Resumen: LIGHTSITE IIIB de LumiThera muestra una mejora visual extensa en sujetos con DMAE seca
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., una compañía de dispositivos médicos que ofrece tratamiento de fotobiomodulación (PBM) para el daño y las enfermedades oculares, ha anunciado hoy los resultados principales del ensayo de extensión LIGHTSITE III…
Les résultats préliminaires de l'essai de prolongation LIGHTSITE IIIB de LumiThera montrent une amélioration prolongée de la vision chez les sujets atteints de DMLA sèche
SEATTLE–(BUSINESS WIRE)–LumiThera Inc. est une société de dispositifs médicaux qui propose des traitements de photobiomodulation (PBM) pour les lésions et les maladies oculaires. Elle a annoncé aujourd’hui les premiers résultats de l’essai de prolong…
Harrow Announces First-Quarter 2025 Financial Results
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. The Company also posted its first quarter Letter to Stockholders …
$7.22 Bn OTC Artificial Tears Market Size, Share Analysis, Growth Trends and Forecasts 2024-2025 & 2033 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “OTC Artificial Tears Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The OTC Artificial Tears market is expected to grow from US$ 4….
Vision Care Market Forecast Report and Company Analysis 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant Pharma, Paragon Vision Science, and Menicon – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The Vision Care Market is anticipated to rise at a compound annual growt…
Warby Parker Announces First Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. “Our team deliver…
LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects Treated with Valeda
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the U…
STAAR Surgical Reports First Quarter 2025 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March…
Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
CAMBRIDGE, England–(BUSINESS WIRE)–Today, Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the trea…